Ibandronate in oncology

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1696-1698

  Burckhardt, Peter ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030879067     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1696::aid-cncr22>3.0.co;2-u     Document Type: Conference Paper

References (12)

1. Gertz BJ, Holland SH, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98.
2. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991;6:1003-XX.
3. Wüster CH, Schöter KH, Thiébaud D, Manegold CH, Krahl D, Clemens MR, et al. Methylpentylaminopropylidenebis-phosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 1993;22:77-85.
4. Pecherstorfer M, Herrmann Z, Body JJ, Manegold CH, Degardin M, Clemens MR, et al. Randomized phase II trial comparing different doses of the bisphosphoante Ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-76.
5. Boehringer Mannheim Study MF 4223. Data on file.
6. Ralston SH, Thiébaud D, Herrmann Z, Steinhauer EU, Thürlimann B, Walls J, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
7. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body JJ. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996;11:587-93.
8. Boehringer Mannheim Study MF 4328. Data on file.
9. Thiébaud D, Husi B, Jacquet AF, Burckhardt P. Effects of ibandronate i.v. bolus injection in healthy men and postmenopausal women (abstract). Presented at the 19th Annual Meeting of the American Society for Bone and Mineral Research, 1997.
10. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, et al. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporo Int 1994;4:76-83.
11. Thiébaud D, Kriegbaum H, Huss H, Christiansen C, Burckhardt P. Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. In: Papapoulos SE, et al., editors. Osteoporosis. New York: Elsevier Science BV, 1996:321-5.
12. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttman JR, et al. Three-monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med, in press.